Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05280470 · ClinicalTrials.gov registry record · Phase 2
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT05280470 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 187 participants, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05280470, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum of 3 prior lines of therapy (Part 1) and a minimum of two previous lines of systemic therapy (Part 2). This study will also investigate I-DXd anti-tumor activity in this population.
Conditions Studied
Interventions
- DRUG Ifinatamab Deruxtecan (I-DXd)
Study Locations (20)
Other
- Jilin Cancer Hospital - Changchun
- Hunan Cancer Hospital - Changsha
- West China Hospital, Sichuan University - Chengdu
- Guangdong Provincial People'S Hospital - Guangdong
Florida
- The Cancer Specialists, Llc - Jacksonville
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Michigan
- Henry Ford Hospital - Detroit
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
New York
- Memorial Sloan-Kettering Cancer Center (Mskcc) - New York - New York
- Montefiore Medical Center Prime - The Bronx
Arkansas
- Highlands Oncology Group - Springdale
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana-Faeber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05280470
The ClinicalTrials.gov registry entry for NCT05280470 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (11% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ifinatamab Deruxtecan (I-DXd) is the first listed.
NCT05280470 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05280470 about?
NCT05280470 is a clinical study titled "Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)". This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemo...
What is the current status of trial NCT05280470?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2022-03-09. Estimated completion is 2026-12-15.
What conditions does trial NCT05280470 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT05280470?
The interventions under investigation include: Ifinatamab Deruxtecan (I-DXd) (DRUG).
Who is sponsoring clinical trial NCT05280470?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05280470 being conducted?
This trial has 20 study locations across Arkansas, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
RECRUITING · Phase 2
-
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.